Skip to main content
SpringerLink
Log in

Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Liver metastases of colorectal cancer is present in more than 20% of new diagnosed patients and in 40–60% of relapsed patients. It is a life-threatening prognostic aspect. Hepatic resection, when possible, is the best therapeutic modality, although the overall survival rate is still low (30%). Angiography and intraoperative ultrasonography are useful for resection. The number of hepatic metastases and the surgical margin are probably the most significant prognostic factors. Colorectal cancer may spread predominantly to the liver making regional treatment strategies viable options. Subtotal hepatic resections and segmentectomies are potentially curable procedures for single or small numbers of hepatic metastases without other sites of disease. However, there have been no prospective randomized trials comparing patients with unresected liver metastases and resected metastases. Regional chemotherapy with floxuridine seems usefull combined with hepatic resection or as palliative therapy. Gastric ulcer and biliary sclerosis are the main related toxicities. Patients with localized, unresectable hepatic metastases or concomitant bad medical condition may be candidates for radiation, percutaneous ethanol injection, cryosurgery, percutaneous radiofrequency, hypoxic flow-stop perfusions with bioreductive alkylating agents, hepatic arterial ligation, embolization and chemoembolization. These new hepatic-directed modalities of treatment are being investigated and may offer new approaches to providing palliation and prolonging survival. This review will report the possibilities of intra-arterial chemotherapy and other novel hepatic-directed approaches to the treatment of liver metastases from colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history.Br J Surg 1990;77: 1241–1246.

    Article  CAS  PubMed  Google Scholar 

  2. Wagner JS, Adson MA, van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment.Ann Surg 1984;199: 502–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy.Cancer 1969;23: 198–202.

    Article  CAS  PubMed  Google Scholar 

  4. Lahr CJet al. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma.J Clin Oncol 1983;1: 720–726.

    Article  CAS  PubMed  Google Scholar 

  5. Japanese Society for Cancer of the Colon and Rectum.Multiinstitutional Registry of Large Bowel Cancer in Japan. Vol. 10: Cases Treated in 1991 and 1992 (Prospective Registry Data), 1995.

  6. Steele G Jret al. Patterns of failure after surgical cure of large liver tumors.Am J Surg 1984;147: 554–559.

    Article  PubMed  Google Scholar 

  7. Leyland-Jones B, Burdette-Radoux S. Management of hepatic metastases from colorectal cancer: systemic chemotherapy.J Gastrointest Surg 1997;1: 576–582.

    Article  CAS  PubMed  Google Scholar 

  8. Leichman CGet al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study.J Clin Oncol 1995;13: 1303–11.

    Article  CAS  PubMed  Google Scholar 

  9. Yasuda Set al. Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis.Gan To Kagaku Ryoho 1990;17: 1815–1819.

    CAS  PubMed  Google Scholar 

  10. Kemeny Net al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma—a randomized trial.Ann Int Med 1987;187: 459–465.

    Article  Google Scholar 

  11. The Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.J Natl Cancer Inst 1996;88: 1252–58.

    Article  Google Scholar 

  12. Harmanthas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver.Cancer 1996;78: 1639–1645.

    Article  Google Scholar 

  13. Rougier Pet al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.J Clin Oncol 1992;10: 1112–1118.

    Article  CAS  PubMed  Google Scholar 

  14. Blank RJ, Tyson IB. Intrarterial131I macroaggregated albumin to define intra-hepatic tumours, a possible method of quantitating tumour response to therapy.J Nucl Med 1966;10: 514–516.

    Google Scholar 

  15. Belluco Cet al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases.J Clin Oncol 1996;14: 2696–2701.

    Article  CAS  PubMed  Google Scholar 

  16. Kemeny Net al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.Cancer 1992;69: 327–334.

    Article  CAS  PubMed  Google Scholar 

  17. Kemeny MM, Alava G, Oliver JM. The effects on liver metastases of circadian patterned continuous hepatic artery infusion of FUDR.Surgery 1994;7: 219–224.

    CAS  Google Scholar 

  18. Kemeny MM, Alava G, Oliver J. The effects on toxicity of circadian patterning of continuous hepatic artery infusion.Surgery 1992;5: 185–194.

    CAS  Google Scholar 

  19. Hrushesky W, von Roemeling R, Lanning R, Rabatin JT. Circadian-shaped infusion of floxuridine for progressive matastatic renal cell carcinoma.J Clin Oncol 1990;8: 1504–1513.

    Article  CAS  PubMed  Google Scholar 

  20. Stagg RJet al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.J Natl Cancer Inst 1991;83: 423–428.

    Article  CAS  PubMed  Google Scholar 

  21. Kemeny Net al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma—New dose schedules and survival update.Cancer 1994;73: 1134–1142.

    Article  CAS  PubMed  Google Scholar 

  22. Kemeny Net al. Hepatic arterial infusion of floxuridine (FUDR) dexamethasone (Dex) and high dose mitomycin C (Mit C): comparable response to FUDR/leucovorin/Dex but with greater toxicity.Proc Am Soc Clin Oncol 1995;14: 201.

    Google Scholar 

  23. Metzger U, Weder W, Rothlin M, Largiader F. Phase II study of intra-arterial fluorouracil and mitomycin C for liver metastases of colorectal cancer.Recent results Cancer Res 1991;121: 198–204.

    Article  CAS  PubMed  Google Scholar 

  24. Kemeny Net al. Randomized trial of hepatic arterial FUDR, mitomycin C and BCNU versus FUDR alone: effective salvage therapy for liver metastases of colorectal cancer.J Clin Oncol 1993;11: 330–335.

    Article  CAS  PubMed  Google Scholar 

  25. Safi F. Continuous simultaneous intraarterial and intravenous therapy of liver metastases of colorectal carcinoma: Results of a prospective randomized trial.Proc Am Soc Clin Oncol 1992;11: 490.

    Google Scholar 

  26. Lorenz M, Hottenrott C, Inglis R, Kirkowa-Reiman M. Prevention of extrahepatic disease during intraarterial floxuridina of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.Gan To Kagaku Ryoho 1989;16: 3662–3671.

    CAS  PubMed  Google Scholar 

  27. O'Connell Met al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.J Clin Oncol 1998;7: 2528–2533.

    Article  Google Scholar 

  28. Russell AHet al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol.Int J Radiat Oncol Biol Phys 1993;27: 117–123.

    Article  CAS  PubMed  Google Scholar 

  29. Wiley ALet al. Combined hepatic artery 5-Fluorouracil and irradiation of liver metastases: a randomized study.Cancer 1989;64: 1783–1789.

    Article  PubMed  Google Scholar 

  30. Ajlouni MIet al. Concomitant radiation therapy and constant infusion FUDR for unresectable hepatic metastases.Am J Clin Oncol 1990;13: 532–535.

    Article  CAS  PubMed  Google Scholar 

  31. Andrews JCet al. Hepatic radioembolization with Yttrium90 containing glass microspheres: Preliminary results and clinical follow-up.J Nucl Med 1994;35: 1637–1644.

    CAS  PubMed  Google Scholar 

  32. Anderson JHet al. Glass yttrium90 microspheres for patients with colorectal liver metastases.Radiother Oncol 1992;25: 137–139.

    Article  CAS  PubMed  Google Scholar 

  33. Thomas DSet al. Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a phase I–II trial.Cancer 1993;71: 1977–1981.

    Article  CAS  PubMed  Google Scholar 

  34. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: Results of percutaneous ethanol injection in 14 patients.Radiology 1991;179: 709–712.

    Article  CAS  PubMed  Google Scholar 

  35. Salim AS. Chemonecrosis for localized dynamic destruction of hepatic metastases of colonic cancer—a new approach.Oncology 1993;50: 8–21.

    Article  Google Scholar 

  36. Ravikumar TSet al. Experimental and clinical observations on hepatic cryosurgery for colorectal metastases.Cancer Res 1991;51: 6323–6327.

    CAS  PubMed  Google Scholar 

  37. Onik Get al. Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results.Cancer 1991;67: 901–907.

    Article  CAS  PubMed  Google Scholar 

  38. Rossi Set al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.Am J Roentgen. 1996;167: 759–768.

    Article  CAS  Google Scholar 

  39. Solbiati Let al. Percutaneous US-guided RF tissue ablation of liver metastases: long-term follow-up.Radiology 1997;202: 195–203.

    Article  CAS  PubMed  Google Scholar 

  40. Livraghi Tet al. Saline-enhanced radiofrequency tissue ablation in the treatment of liver metastases.Radiology 1997;202: 205–210.

    Article  CAS  PubMed  Google Scholar 

  41. Solbiati Let al. Hepatic metastases percutaneous radio-frequency ablation with cooled-tip electrodes.Radiology 1997;205: 367–373.

    Article  CAS  PubMed  Google Scholar 

  42. Roversi Ret al. Antiblastic hypoxic stop-flow perfusion in the treatment of liver metastases: preliminary results.Radiol Med 1997;93: 410–417.

    CAS  PubMed  Google Scholar 

  43. Fiorentini Get al. Intraortic stop flow infusion with hypoxic abdominal perfusion in UICC stage III/IV pancreatic carcinoma: report of a phase II study.Reg Cancer Treat 1996;9: 88–91.

    Google Scholar 

  44. Fiorentini Get al. Hypoxic isolated limb perfusion with mitomycin C in locally recurrent melanoma and sarcoma: results of a phase II study.Reg Cancer Treat 1995;8: 135–139.

    Google Scholar 

  45. Aigner KR, Kaevel K. Pelvic stop flow infusion (PSI) and hypoxic pelvic perfusion (HPP) with Mitomycin and Melphalan for recurrent rectal cancer.Reg Cancer Treat 1994;1: 6–11.

    Google Scholar 

  46. Petrelli NJet al. Hepatic artery ligation for liver metastasis in colorectal carcinoma.Cancer 1984;53: 1347–1353.

    Article  CAS  PubMed  Google Scholar 

  47. Gerard Aet al. Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma.Eur J Surg Onc 1991;17: 289–294.

    CAS  Google Scholar 

  48. Allison DJ, Modlin IM, Jenkins WJ. Treatment of carcinoid liver metastases by hepatic-artery embolization.Lancet 1977;24: 1323–1325.

    Article  Google Scholar 

  49. Gyves JWet al. Improved regional selectivity of hepatic arterial mitomycin by starch microspheres.Clin Pharmacol Ther 1983;34: 259–265.

    Article  CAS  PubMed  Google Scholar 

  50. Epenetos AAet al. Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres.Nucl Med Commun 1987;8: 1047–1058.

    Article  CAS  PubMed  Google Scholar 

  51. Daniels Jet al. Phase I trial with cisplatin or mitomycin hepatic chemoembolization (CE) with angiostat collagen for embolization (CFE) in patients with colorectal cancer.Proc Am Soc Clin Oncol 1988;7: 385 (abstract).

    Google Scholar 

  52. Civalleri Det al. Treatment of patients with irresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres.Br J Surg 1994;81: 1338–1341.

    Article  CAS  PubMed  Google Scholar 

  53. Fiorentini G, Cariello A, Giovanis P, Turci D, Dazzi C. Amifostine as modulator of hepatic (HT) and biliary toxicity (BT) from intra-arterial chemoembolization (IAHC): results of a phase I study.Ann Oncol 1998;9 (S2): 55–56.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery and Locoregional Treatments, City Hospital ASL Ravenna, Ravenna, Italy

    DB Poddie & D Guglielminetti

  2. Department of Oncology and Hematology, City Hospital, ASL Ravenna, viale Randi 5, 48100, Ravenna, Italy

    G Fiorentini, U De Giorgi, P Giovanis, M Leoni, W Latino, C Dazzi, A Cariello, D Turci & M Marangolo

Authors
  1. G Fiorentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. DB Poddie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U De Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Guglielminetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Giovanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Leoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Latino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Dazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Cariello
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Turci
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Marangolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Fiorentini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiorentini, G., Poddie, D., De Giorgi, U. et al. Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments. Med Oncol 17, 163–173 (2000). https://doi.org/10.1007/BF02780523

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02780523

Keywords

Search

Navigation